Will GEO Group report FY2026 revenue at or above $2.9 billion?

The $2.9B floor is the low end of management's $2.9-3.1B guidance range. FY2025 revenue was $2.63B, so $2.9B requires $270M incremental revenue (+10.3%). Identifiable sources: $520M annualized contract wins (partial-year recognition), skip tracing ($60M/yr new stream), Florida DOC ($100M annualized starting July 2026, ~$50M H2 contribution). Q4 2025 alone was $708M annualized to $2.83B. The run rate plus identified new revenue streams strongly support exceeding $2.9B unless there's a material disruption (government shutdown, contract cancellation). Q1 is guided at $680-690M (seasonal), implying $2.72-2.76B annualized — the back-half ramp needs to deliver.

The math supports exceeding $2.9B: Q4 2025 at $708M is the best quarterly run rate. New revenue sources (skip tracing, Florida DOC) add incremental contribution. However, Q1 2026 is guided lower ($680-690M), and back-half weighting means risk is concentrated in H2 execution. Government shutdown risk from DHS continuing resolution is a tail risk. The $520M in contract wins is annualized — actual FY2026 contribution depends on activation timing and ramp. Reducing slightly from 80% due to execution risk on timing.

Record ICE census of 24,000 provides a strong revenue floor for the core business. Skip tracing ($60M/yr) and Florida DOC ($100M annualized, H2 activation) provide clearly identified incremental streams. The question is whether the guidance floor is conservative or tight. Given Q1 guided at $680-690M and the back-half ramp, implied Q2-Q4 average needs to be ~$740-750M to hit $2.9B. Q4 2025 was $708M, so this requires continued growth trajectory. Achievable but requires sustained execution.

Management guided $2.9-3.1B with $520M in identified contract wins already secured. The low end ($2.9B) is only 10% above FY2025 — modest growth for a company with record demand. Q4 2025 revenue of $708M was +16.4% YoY, showing accelerating momentum. Record ICE census, new skip tracing contract, and Florida DOC activations all provide identifiable revenue upside. Management would need to significantly miss guidance to fall below $2.9B, which would require a material disruption like a government shutdown.

The guidance floor of $2.9B is well-supported by identified revenue sources. However, I'm moderating slightly because: (1) Q1 guided at $680-690M is below Q4 run rate, (2) back-half weighted guidance introduces execution risk, (3) start-up costs and timing of contract activations may not perfectly align with calendar year. Government operations risk from potential shutdown or continuing resolution is real but manageable. Base case: GEO hits guidance floor or exceeds it.

Management's track record of beating Q4 2025 expectations by 16.4% and securing $520M in contract wins suggests guidance is achievable. The $2.9B floor requires minimal additional growth beyond identified revenue sources. ISAP contract repricing creates some margin headwind but doesn't reduce top-line revenue. The most likely path to missing $2.9B involves a macro disruption (government shutdown, ICE budget sequestration) rather than operational underperformance.

Low end of guidance with record demand and $520M in contract wins. Q4 2025 revenue trajectory supports continued growth. Skip tracing and Florida DOC provide incremental revenue. High probability of meeting guidance floor. Only government shutdown or major contract cancellation would cause a miss.

Strong fundamentals support $2.9B floor. Some execution risk from back-half weighting and start-up costs. Government shutdown tail risk is real but low probability. 70-80% range is appropriate for meeting the low end of a well-supported guidance range.

The math works: Q4 run rate plus identified new revenue streams support exceeding $2.9B. Management guided conservatively with Q1 below Q4, suggesting the full-year floor has cushion built in. 77% probability reflects high confidence in the floor with a discount for execution timing and macro risks.